Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in Australia in its international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer (NSCLC). The study, also ongoing in mainland China and the United States, aims to evaluate the efficacy and safety of HLX43. Previous phase 1 results demonstrated promising response rates and safety profiles, particularly in patients with advanced tumors who have not responded to other treatments, indicating potential significant impact on the company’s market positioning in oncology therapeutics.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company focused on the development of innovative biologic drugs, particularly antibody-drug conjugates (ADCs) for the treatment of advanced and metastatic solid tumors. The company is actively involved in clinical trials across various regions, including mainland China, the United States, and Australia, with a market focus on oncology therapeutics.
Average Trading Volume: 1,489,687
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.27B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.